TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02448602

Intervention type: OTHER
Group type: OTHER
Intervention: acupuncture
Description: Patients will be treated with Shenmen(HT7), needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: acupuncture
Description: Patients in Sancai coordinated points group, will be treated with Baihui(DU20), Shenmen(HT7), Sanyinjiao(SP6), needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: acupuncture
Description: Patients in Control group, will be treated with at the junction of deltoid and biceps, needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
Study: NCT01251653

Intervention type: DRUG
Intervention: Afatinib
Description: Maximum Tolerated Dose of Afatinib in combination with gemcitabine

Intervention type: DRUG
Intervention: Afatinib
Description: Maximum Tolerated Dose of Afatinib in combination with gemcitabine

Intervention type: DRUG
Intervention: docetaxel
Description: Maximum Tolerated Dose of Afatinib in combination with docetaxel

Intervention type: DRUG
Intervention: gemcitabine
Description: Maximum Tolerated Dose of Afatinib in combination with gemcitabine
Study: NCT02268279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solithromycin
Study: NCT02707120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRGF-Endoret
Description: Active treatment will be PRP eye drops obtained by the PRGF-Endoret system.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artificial tears eye-drops
Description: Artificial tear moisturizing eyedrops (Hidrathea®, Nacl 0.9 % solution without preservatives).
Study: NCT03333720

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phenylalanine-free protein substitute tablets
Description: Thirty eligible PKU patients (≥ 8 years), identified as current tablet users, will be recruited to this study. Patients will firstly observe a 7-day baseline period. During baseline, patients will continue with their existing diet and protein substitute prescription before receiving Phenylalanine-free protein subsitute tablets daily for 28 days in addition to appropriate nutritional management.
Study: NCT01012791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zumba exercise
Description: Subjects with do Zumba exercise for approximately 60 minutes twice a week for 6 months.
Study: NCT04284202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 plus Dasatinib
Description: Toripalimub 240mg injection day1; Dasatinib 100mg po qd day1-day21. 3weeks is 1 cycle.
Study: NCT02137512

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-Loop Control System
Description: This investigational device system included the following components:~* DiAs - a smart-phone medical platform;~* Dexcom G4 Platinum CGM system connected to DiAs via CGM receiver and USB-Bluetooth relay hardware;~* Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth;~* Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network~* Modular Closed-Loop Control Algorithm Running on DiAs, which is of Control-to-Range (CTR) class

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sensor-Augmented Pump (SAP)
Description: This commercial device system included the following components:~* Dexcom G4 Platinum CGM system;~* Roche Accu-Chek insulin pump
Study: NCT04012554

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: avoid chest drainage tube placement after video-assisted thoracoscopic wedge resection of lung
Description: Avoiding chest drainage tube placement after VATS of the lung in the experiment group.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Indewlling chest drainage tube after video-assisted thoracoscopic wedge resection of lung
Description: Indewlling chest drainage tube after VATS of lung in the control group.
Study: NCT03906097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Play and Competition-Based Cognitive Therapy
Description: The intervention group was received play and competition-based cognitive therapy for 10 weeks, 3 days a week, 1 hour per day; the control group was the group who continued the special education program
Study: NCT03650842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near infrared spectroscopy (NIRS)
Description: One monitor will be placed on the forehead to measure cerebral oxygenation and a second over the lower back to measure tissue (muscle or renal) oxygenation.
Study: NCT04171375

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: trans-spinal Electrical Stimulation (tsES)
Description: The trans-spinal pulsed-current stimulation utilizes non-invasive russian stimulation using a research grade stimulator and direct-current stimulation utilizes non-invasive constant stimulation using a medical grade stimulator. Both pulsed- and direct-current stimulation will be achieved with cutaneous cathode electrodes attached to the dorsal aspect of the back overlying at and bellow thoracic vertebrae and anode electrodes placed over the iliac crests or lower abdomen. Spinal motor evoked potentials will be induced by trans-spinal pulsed-current stimulation (parameters, 1 Hz with a 1 millisecond pulse width and monophasic waveform) to determine recruitment profiles of proximal and distal motor pools with increasing stimulation intensity ranging from 10-200 milliampere. Stimulation parameters for the therapeutic stimulation will be ranged from 5-50 Hz and 20-200 milliampere. For direct-current stimulation, the stimulation current will be kept constant at 2-2.5 milliampere.
Study: NCT04265846

Intervention type: DEVICE
Intervention: bifocal IOL
Description: The patients will undergo bilateral phacoemulsification and bifocal IOLs implantation.

Intervention type: DEVICE
Intervention: mix bifocal IOL
Description: The patients will undergo phacoemulsification and mix different bifocal IOLs implantation bilaterally.

Intervention type: DEVICE
Intervention: trifocal IOL
Description: The patients will undergo bilateral phacoemulsification and trifocal IOLs implantation.

Intervention type: DEVICE
Intervention: EDOF IOL
Description: The patients will undergo bilateral phacoemulsification and EDOF IOLs implantation.

Intervention type: DEVICE
Intervention: different IOLs
Description: The patients will undergo phacoemulsification and different IOLs implantation bilaterally.

Intervention type: DEVICE
Intervention: monofocal IOL
Description: The patients will undergo bilateral phacoemulsification and monofocal IOLs implantation with monovision designed.

Intervention type: DEVICE
Intervention: monofocal IOL
Description: The patients will undergo bilateral phacoemulsification and monofocal IOLs implantation with emmetropia designed.
Study: NCT01981915

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IPPB
Description: Lung insufflation with positive pressure using IPPB up from 10 to 40 mbar in 5 mbar increments and consecutive measurement of the insufflation volume

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IPPB
Description: Lung insufflation with positive pressure using IPPB up from 10 to 40 mbar in 5 mbar increments and consecutive measurement of the insufflation volume

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LIAM
Description: Lung insufflation using the Lung Insufflation Assist maneuver of the Ventilogic LS mechanical ventilator (Weinmann Germany) with positive pressure up from 10 to 40 mbar in 5 mbar increments and consecutive measurement of the insufflation volume

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LIAM
Description: Lung insufflation using the Lung Insufflation Assist maneuver of the Ventilogic LS mechanical ventilator (Weinmann Germany) with positive pressure up from 10 to 40 mbar in 5 mbar increments and consecutive measurement of the insufflation volume
Study: NCT04551937

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lactose Free 1% Milk
Description: 8 oz of study beverage daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactose Free 1% Milk + 10 g prebiotic
Description: 8 oz of study beverage supplemented with 5 grams of fructooligosaccharide and 5 grams of galactooligosaccharide
Study: NCT04027400

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: computer-assisted rehabilitation
Description: Participant is presented with 10 exercises a day, 3 minutes each. When participant achieves 100% accuracy of the exercise, he/she gets a higher level of exercise. Levels of range from 1-9. Exercises are changed every week by researcher.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: computer-assisted rehabilitation
Description: Participant is presented with 10 exercises a day, 3 minutes each. When participant achieves 100% accuracy of the exercise, he/she gets a higher level of exercise. Levels of range from 1-9. Exercises are changed every week by researcher.
Study: NCT04599777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE combined with sorafenib and tislelizumab
Description: Sorafenib (400mg P.O. Bid) and tislelizumab (200mg I.V. q3w) will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated. Treatment of tislelizumab will last up to 24 months. Patients will be allowed to have sorafenib or tislelizumab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
Study: NCT04193007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: molecular targeted therapies
Description: if EGFR mutation is positive, (gefitinib, ecotinib, erlotinib）or ALK/ROS-1 positive（Crizotinib）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: molecular targeted therapies
Description: if EGFR mutation is positive, (gefitinib, ecotinib, erlotinib）or ALK/ROS-1 positive（Crizotinib）

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brain Radiotherapy
Description: SRS was used for 1-3 intracranial lesions, and simultaneous modulated accelerated radiation therapy for Brain(SMART-Brain)was used for more than 3 intracranial lesions
Study: NCT01365260

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MM-II
Description: Single intraarticular (knee) injection of MM-II

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DurolaneTM
Description: Single intraarticular (knee) injection of DurolaneTM
Study: NCT03373097

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GD2-CART01
Description: Following a lymphodepleting treatment with conventional chemotherapy, patients will be treated with 1.0 to 10.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
Study: NCT04179734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bremelanotide
Description: Melanocortin-4 receptor agonist subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bremelanotide
Description: Melanocortin-4 receptor agonist subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo subcutaenous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaenous injection.
Study: NCT04027114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized behavioural physical activity intervention
Description: • The intervention involves a tailored physiotherapy (PT) intake that will serve as the foundation for the individualized approach. Participants' individual attributes and physical activity needs, including a general PT assessment will occur initially. Over the next 12 months, participants will receive individualized PT coaching and a physical activity plan plus access to educational literature that outlines methods and benefits of exercise. An estimated 15 hours of PT contact hours per participant is anticipated and the specifics of each encounter will be documented.
Study: NCT02966509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EPAC
Description: Each patient will receive a lay health worker who will engage and educate patients on goals of care documentation and will continue to address goals of care for at least 6 months with patients after enrollment in the study.
Study: NCT01389167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vivitrol
Description: An extended release naltrexone formulation for intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vivitrol
Description: An extended release naltrexone formulation for intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone (oral)
Description: Naltrexone 50 mg pills, daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone (oral)
Description: Naltrexone 50 mg pills, daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BDRC
Description: Manual-guided BDRC is a highly structured, educational, prescriptive, and individualized treatment that focuses on the patient's current problem areas that are immediately related to marinating abstinence in order to achieve sustained recovery from drugs. The primary goals of BDRC include education about the disease of opiate dependence and effective treatment approaches, skills and strategies to maintain drug abstinence following detoxification, reduction/cessation of drug and sexual behaviors associated with HIV transmission, and increased engagement in non-drug-related social interactions and pleasurable activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BDRC
Description: Manual-guided BDRC is a highly structured, educational, prescriptive, and individualized treatment that focuses on the patient's current problem areas that are immediately related to marinating abstinence in order to achieve sustained recovery from drugs. The primary goals of BDRC include education about the disease of opiate dependence and effective treatment approaches, skills and strategies to maintain drug abstinence following detoxification, reduction/cessation of drug and sexual behaviors associated with HIV transmission, and increased engagement in non-drug-related social interactions and pleasurable activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Management
Description: Patient assigned to MM will receive manual-guided medically oriented counseling approximating the current standard of care provided in with NTM the Russian Federation, consisting of an initial introductory session (introduction to NMT and basic education about HIV risks) and subsequent, brief (up to 20 minutes) support and advice sessions once per month.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Management
Description: Patient assigned to MM will receive manual-guided medically oriented counseling approximating the current standard of care provided in with NTM the Russian Federation, consisting of an initial introductory session (introduction to NMT and basic education about HIV risks) and subsequent, brief (up to 20 minutes) support and advice sessions once per month.
Study: NCT02258789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR-method
Description: Neglect rehabilitation by intense scanning training and multi sensory stimuli using Virtual Reality
Study: NCT01086462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2239633
Description: 100 ug GSK2239633 containing approximately 10kBq \[14C\]-GSK2239633
Study: NCT02644564

Intervention type: OTHER
Intervention: Ultrasonography
Description: One doctor does the clinical examination, another does ultrasonography. Both doctors and patient are blinded until results have been registered on written forms. The results are then disclosed to the patient and doctors in order to plan further treatment.
Study: NCT02263079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Participants will receive entecavir, either as a film-coated tablet or oral solution, once daily at a dose of 0.015 milligrams per kilogram (mg/kg) (maximum daily dose of 0.5 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Participants will receive lamivudine, either as a film-coated tablet or oral solution, once daily at a dose of 3 mg/kg (maximum daily dose of 100 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa-2A
Description: Participants will receive pegylated interferon-alfa-2A at a body surface area (BSA) based dose of 180 micrograms per 1.73 square meter (mcg/1.73m\^2) BSA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa-2A
Description: Participants will receive pegylated interferon-alfa-2A at a body surface area (BSA) based dose of 180 micrograms per 1.73 square meter (mcg/1.73m\^2) BSA.
Study: NCT00199550

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar Transurethral Resection of the Prostate
Description: Bipolar TURP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monopolar Transurethral Resection of the Prostate
Description: Monopolar TURP
Study: NCT02965521

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Website and text messages
Description: Participants receive a personalized diet report, access to a digital health dietary intervention, and text messages for 12 weeks.
Study: NCT00019708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV
Study: NCT01199042

Intervention type: DEVICE
Group type: OTHER
Intervention: BiPAP autoSV Advanced
Description: The sleep apnea device will be set-up in automatic mode with the settings wide open for the entire night.
Study: NCT02053168

Intervention type: DEVICE
Group type: OTHER
Intervention: Resorbable Mesh
Description: Phasix Mesh
Study: NCT02905370

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Multi-Component (PMC)
Description: Participants in the Progressive Multi-component intervention group will receive 1) high intensity physical therapy, 2) protein supplement, and 3) emphasis on functionally enhanced transitions of care following discharge from post-acute setting. High intensity physical therapy will include progressive resistance training, multi-planar motor control and gait exercises, and high intensity activities of daily living training. Functionally enhanced transitions of care protocol includes a personal health record with 5 domains that are addressed in an interdisciplinary manner with the patient. Participants will receive 12 intervention visits over 60 days. Participants will also receive a home exercise program.
Study: NCT01194856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir
Description: 300 mg orally once daily with Ritonavir 100mg orally once daily for 96 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: Maintain dosage - 600 mg orally QHS for 96 weeks
Study: NCT01491607

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BioThrax
Description: BioThrax, 0.5 mL administered subcutaneously on days 0, 14, and 28.
Study: NCT02905370

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: Participants in the Enhanced Usual Care group will receive standardized physical therapy following discharge from acute hospitalization. The activities of therapy will include basic strength training, single-planar motor control and gait exercises, and activities of daily living training. Participants will receive 12 intervention visits over 60 days. Participants will also receive a standardized home exercise program and standard nutritional education.~Name of Participant Arm updated to Enhanced Usual Care from Usual Care effective 8/16/18 to distinguish from Passive Comparator True Usual Care group.
Study: NCT02122328

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sequential laser photocoagulation of communicating vessels.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective laser photocoagulation of communicating vessels
Study: NCT01114503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otelixizumab - low dose
Description: 8 day dose rising intravenous infusions of a low dose of otelixizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otelixizumab - medium low dose
Description: 8 day dose rising intravenous infusions of a medium low dose of otelixizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otelixizumab - medium high dose
Description: 8 day dose rising intravenous infusions of a medium high dose of otelixizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otelixizumab - high dose
Description: 8 day dose rising intravenous infusions of a high dose of otelixizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otelixizumab
Description: 8 day dose rising intravenous infusions of otelixizumab administered at a dose decided upon results from Part A.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Weekly intravenous infusions of methylprednisolone administered as 500 mg per week for 6 weeks and then 250 mg per week for 6 weeks
Study: NCT01602770

Intervention type: DRUG
Intervention: EV/DNG (Qlaira, BAY86-5027)
Description: Qlaira is taken daily continously with no pause between cycles in a four-phasic dose regimen, making up a treatment of up to 28 days. The first two tablets contain 3 mg Estradiol Valerate (E2V). The next five tablets include 2 mg E2V and 2 mg Dienogest (DNG) followed by 17 tablets with 2 mg E2V and 3 mg DNG. Finally, there are two tablets with 1 mg E2V and two placebo tablets.
Study: NCT01748175

Intervention type: DRUG
Intervention: Triamcinolone Acetonide
Description: Each subject that meets inclusion/exclusion criteria will receive triamcinolone acetonide intramuscularly at the end of visit 2. Adults ≥18 years will receive 40 mg triamcinolone acetonide. Children 6-17 years will receive 1 mg/kg triamcinolone acetonide (up to 40 mg maximum). Triamcinolone acetonide will be administered as a single intramuscular dose deep in the gluteal region
Study: NCT03446222

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: Catheter based radiofrequency ablation with wide antral circumferential PVI and isolation of posterior wall will be performed. Mitral and cavo-tricuspid isthmus ablation will be done only if such isthumus dependent flutters are documented prior to / during the procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini-maze surgical procedure
Description: Wolf Mini-maze surgical ablation along with left atrial appendage ligation will be performed.
Study: NCT00983177

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: 0.5 mg twice daily for 4 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lactose
Description: lactose capsules twice daily
Study: NCT01234974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Description: Given as an intramuscular injection on day 1 every 28 days, 60 mg per dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: given as an oral tablet every day on days 1-28, 10 mg per day